{"id":"W2765091613","doi":"10.1093/rheumatology/kex396","title":"Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis","year":2017,"lang":"en","type":"article","venue":"Lara D. Veeken","topic":"Systemic Sclerosis and Related Diseases","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"ca_institutions":"Jewish General Hospital; Western University","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Allergy and Infectious Diseases; Genentech; National Institutes of Health","keywords":"Medicine; Placebo; Tocilizumab; Scleroderma (fungus); Visual analogue scale; Internal medicine; Clinical endpoint; Physical therapy; Clinical trial; Rheumatoid arthritis; Immunology; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001975998,0.0007471275,0.00214335,0.0002873112,0.0002104149,0.0006532173,0.0003469247,0.0009435316,0.002611076],"category_scores_gemma":[0.001555255,0.0002183407,0.001447355,0.0003103598,0.000601217,0.0005024627,0.000241317,0.00147647,0.0002539161],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002915573,"about_ca_system_score_gemma":0.0003037728,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004045719,"about_ca_topic_score_gemma":0.0008021791,"domain_scores_codex":[0.9991102,0.0005911844,0.00006887718,0.00007826235,0.00008244595,0.00006910699],"domain_scores_gemma":[0.9987361,0.0004934233,0.0003598549,0.00006396403,0.00005571806,0.0002909437],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9410893,0.004590852,0.003562548,0.00117503,0.002237837,0.00009246328,0.0001200238,0.0003878453,0.007201859,0.00005231639,0.0004761308,0.03901378],"study_design_scores_gemma":[0.6909667,0.2677042,0.03613443,0.0001162401,0.002293041,0.0002171807,0.00008268935,0.0005998635,0.0009817122,0.0001393838,0.0007358858,0.00002872154],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9914396,0.00684008,0.0001262275,0.0002807036,0.00007101659,0.0002670379,0.0003256421,0.00002409899,0.0006256147],"genre_scores_gemma":[0.9965439,0.001771193,0.0002067734,0.0002372374,0.0001409503,0.0003001546,0.0003452917,0.00000477792,0.0004497334],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002611076,"threshold_uncertainty_score":0.01045018,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03283349459928817,"score_gpt":0.2548979141579647,"score_spread":0.2220644195586765,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}